The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The large constant seller over the last couple of months seems to have either finished or given up the ghost. Since no large shareholder has declared a reduction in holding, am just wondering if it was a short seller who now might have a bit of a problem on his hands.
From minute 33.30.....https://www.youtube.com/watch?v=vY6KLjNsXfw
https://www.dailymail.co.uk/health/article-10224601/Is-Covid-trigger-tsunami-type-2-diabetes.html ... imagine on a worldwide basis
BTB, why dont any of you guys who are so negative on the stock short the hell out of it if you can and see where the price is in 6 months? Otherwise move on and leave us in peace… dont waste your time here
Does anyone know how to make a complaint over the spread in this stock. There are over 300 mln shares in issue, and plenty of liquidity. I believe that the market makers deliberately have a wide spread in the stock so that it is impossible to know if any given trade is a buy or a sell. The spread today is currently 8.53% which is ridiculous. Something should be done about this...I speak as an ex market maker myself.
https://www.lse.co.uk/rns/MXCT/license-with-nkarta-inc-viuvv98c4zb1kgp.html
Liambooth, your last post is really scraping the barrel. I worked in the city for over 30 years. Lombard Odier Asset Management makes investments for their clients. As they say on their website their aim is ¨Meeting clients´ objectives by actively shaping sustainable investment outcomes that really add value¨. Do you honestly believe that Asset Management Companies try to support share prices in companies whose price is falling? The only reason they would increase their stake in a company is if they fundamentally believe the current price is attractive enough to warrant the investment. If they believed they had made a bad investment, they would look to divest their holding, not increase it. They certainly would not increase their stake just to support the share price. They are answerable to their client base, and would only end up losing clients if they did what you are suggesting.
Proteomics Could Be the Next ‘Omics Frontier
Simon-Barnett By Simon Barnett | @sbarnettARK
Analyst
The ‘omics revolution describes how technology is transforming our understanding of the fundamental building blocks of life. Starting with the Human Genome Project more than 20 years ago, next-generation DNA sequencing accelerated the genomics revolution. Thanks to recent research breakthroughs, next generation sequencing (NGS) instruments can study the transcriptome—the collection of RNA molecules in an organism. The natural next step for the ‘omics revolution, in our view, is proteomics—the analysis of proteins.
Proteomics involves the study of the three-dimensional structure and sequence of protein molecules. Improvements in mass-spectrometry and novel techniques like Cryo-EM are helping researchers identify the structure of proteins. A few weeks ago, Google’s DeepMind shocked the world with AlphaFold (v2), a neural-network-based algorithm capable of converting a protein sequence into an accurate structural prediction.
Absent still is the ability to develop high-throughput, high-accuracy next-generation protein sequencing (NGPS). In our view, NGPS is lagging behind NGS because of several engineering obstacles. Among them are:
The proteome could have 1,000,000 unique molecules while the transcriptome has 100,000 and the genome 20,000 (genes).
The proteome is changing constantly inside our bodies, both tissue-to-tissue and time-to-time, while the genome is fairly conserved.
Proteins include 20 unique molecules (amino acids) while DNA and RNA have four (4) bases.
Proteins often are less thermodynamically stable than RNA and DNA.
Nature has evolved natural enzymes, such as polymerases, that assist in DNA and RNA sequencing. Proteins do not have the same luxury.
Life sciences entrepreneur, Jonathan Rothberg, is exploring this new frontier. His company, Quantum SI (private), recently filed a patent that describes NGPS methods and compositions addressing many of these challenges. In our view, an instrument capable of sequencing proteins with single-molecule accuracy and high sample throughput - cost-effectively - could turbocharge the ‘omics revolution.